Protocol No.: 20230016

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects with Limited-Stage Small-Cell Lung Cancer (LS-SCLC) who Have Not Progressed Following Concurrent Chemoradiation Therapy (DeLLphi-306)
Principal Investigator
Almubarak, Mohammed
Phase
III
Age Group
Adult
Applicable Disease Site
Lung Cancer
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Carla Ross, RN
Senior Research Nurse
Phone: +1 304-293-2633

View on ClinicalTrials.gov